Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Launched by DONG-A ST CO., LTD. · Mar 12, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term safety and effectiveness of a treatment called Growtropin®-II for children who are shorter than average. The study aims to help children with conditions like growth hormone deficiency (where the body doesn’t produce enough growth hormone), idiopathic short stature (where the cause of shortness is unknown), Turner syndrome (a genetic condition affecting girls), and those who were small for their age at birth. If your child has been diagnosed with one of these conditions and has had their height measured at least six months ago, they may be eligible to participate.

In this trial, children of all genders aged 2 years and older can take part. Participants will receive Growtropin®-II treatment and will be monitored over time to see how well it works and if there are any side effects. This study is currently recruiting, which means they are looking for children to join. If you have any questions or are interested in finding out more, it would be a good idea to talk to your child's doctor about this opportunity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
• • Children who has official height record at least 6 months prior
• Exclusion Criteria:
• • Children with Epiphyseal closure